CAPTRUST Financial Advisors
ONCY

CAPTRUST Financial Advisors’s Oncolytics Biotech ONCY Stock Holding History

CAPTRUST Financial Advisors’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1
Closed – – 5068
2021
Q4 		$0 Buy
+1
New +$2 ﹤0.01% 4868
2021
Q3 		– Sell
-1
Closed – – 4725
2021
Q2 		$0 Sell
1
-500
-100% -$1.53K ﹤0.01% 4617
2021
Q1 		$2K Buy
+501
New +$1.5K ﹤0.01% 4065
2019
Q3 		– Sell
-440
Closed -$1K – 1995
2019
Q2 		$1K Buy
+440
New +$798 ﹤0.01% 1870

Other funds holding ONCY

IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return
CIBC World Market
CIBC World Market Toronto, Ontario, Canada $61.3B AUM 39.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

CAPTRUST Financial Advisors's ONCY Position: Q1 2022 in Review

CAPTRUST Financial Advisors sold out of Oncolytics Biotech (ONCY) in Q1 2022, closing a stake of 1 share.

CAPTRUST Financial Advisors first reported a position in ONCY in Q2 2019 and held it in 4 quarters. The position peaked at $2K in Q1 2021. 41 funds tracked by Wall St. Rank hold ONCY as of Q1 2022.

  • CAPTRUST Financial Advisors reported no remaining Oncolytics Biotech position as of Q1 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 1 Oncolytics Biotech share in Q1 2022.
  • CAPTRUST Financial Advisors first reported a position in Oncolytics Biotech in Q2 2019 and held it in 4 quarters.
  • CAPTRUST Financial Advisors's Oncolytics Biotech position peaked at $2K in Q1 2021.
  • 41 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q1 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q1 2022, filed 16 May 2022.